Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Foghorn Therapeutics (Nasdaq: FHTX), a clinical-stage biotech company focused on developing medicines that correct abnormal gene expression, has announced its participation in three upcoming investor conferences in September 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Foghorn Therapeutics (Nasdaq: FHTX), a clinical-stage biotech company focused on developing medicines that correct abnormal gene expression, has announced its participation in three upcoming investor conferences in September 2025.
The company will attend Citi's 2025 Biopharma Back to School Summit on September 3, the 2025 Wells Fargo Healthcare Conference on September 4, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8. Management will conduct one-on-one meetings at all three events.
Foghorn's Gene Traffic Control® platform focuses initially on oncology applications, aiming to develop treatments for a broad spectrum of diseases.
Details
News Market Reaction – FHTX
On Aug 27, the day this news came out, FHTX closed 2.17% below the previous close.
Data tracked by StockTitan Argus for the Aug 27 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- August 27, 2025 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in Citi’s 2025 Biopharma Back to School Summit, 2025 Wells Fargo Healthcare Conference, and Morgan Stanley 23rd Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Citi’s 2025 Biopharma Back to School Summit
- Date: Wednesday, September 3, 2025
- Management will participate in one-on-one meetings
2025 Wells Fargo Healthcare Conference
- Date: Thursday, September 4, 2025
- Management will participate in one-on-one meetings
Morgan Stanley 23rd Annual Global Healthcare Conference
- Date: Monday, September 8, 2025
- Management will participate in one-on-one meetings
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
khellsvik@foghorntx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.